BR112022009898A2 - Composições e métodos para desrepressão de genes alvo do fator de transcrição silenciador de re1 - Google Patents

Composições e métodos para desrepressão de genes alvo do fator de transcrição silenciador de re1

Info

Publication number
BR112022009898A2
BR112022009898A2 BR112022009898A BR112022009898A BR112022009898A2 BR 112022009898 A2 BR112022009898 A2 BR 112022009898A2 BR 112022009898 A BR112022009898 A BR 112022009898A BR 112022009898 A BR112022009898 A BR 112022009898A BR 112022009898 A2 BR112022009898 A2 BR 112022009898A2
Authority
BR
Brazil
Prior art keywords
seq
compositions
methods
transcription factor
derepression
Prior art date
Application number
BR112022009898A
Other languages
English (en)
Inventor
NESTI Edmund
Pisarchik Alexander
Original Assignee
Alcamena Stem Cell Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcamena Stem Cell Therapeutics Llc filed Critical Alcamena Stem Cell Therapeutics Llc
Publication of BR112022009898A2 publication Critical patent/BR112022009898A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03016—Phosphoprotein phosphatase (3.1.3.16), i.e. calcineurin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/06—Fusion polypeptide containing a localisation/targetting motif containing a lysosomal/endosomal localisation signal

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

COMPOSIÇÕES E MÉTODOS PARA DESREPRESSÃO DE GENES ALVO DO FATOR DE TRANSCRIÇÃO SILENCIADOR DE RE1. A invenção se refere a compostos, composições e métodos para desreprimir genes alvo do fator de transcrição de silenciamento de RE1 (REST). Em particular, um peptídeo com a sequência TEDLEPPEPPLPKEN (SEQ. ID NO: 1) e EDLEPPEPPLPK (SEQ. ID NO: 15), ou as sequências reversas feitas de D-aminoácidos (retro invertido, RI) nekplppeppeldet (SEQ ID NO: 16) e kplppeppelde (SEQ ID NO: 17), são divulgados para inibir a atividade de REST. Os peptídeos são úteis para tratar, prevenir ou melhorar condições como lesão cerebral traumática, epilepsia, demência, doença de Huntington (HD), dor crônica, câncer cerebral (incluindo glioblastoma multiforme), câncer pancreático; diabetes e lesão de nervos periféricos.
BR112022009898A 2019-11-22 2020-11-20 Composições e métodos para desrepressão de genes alvo do fator de transcrição silenciador de re1 BR112022009898A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962939149P 2019-11-22 2019-11-22
US202063086248P 2020-10-01 2020-10-01
PCT/US2020/061632 WO2021102345A1 (en) 2019-11-22 2020-11-20 Compositions and methods for derepressing re1 silencing transcription factor target genes

Publications (1)

Publication Number Publication Date
BR112022009898A2 true BR112022009898A2 (pt) 2022-09-06

Family

ID=75981713

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022009898A BR112022009898A2 (pt) 2019-11-22 2020-11-20 Composições e métodos para desrepressão de genes alvo do fator de transcrição silenciador de re1

Country Status (11)

Country Link
US (1) US20230059411A1 (pt)
EP (1) EP4061833A4 (pt)
JP (1) JP2023503920A (pt)
KR (1) KR20220104008A (pt)
CN (1) CN115023434A (pt)
AU (1) AU2020386637A1 (pt)
BR (1) BR112022009898A2 (pt)
CA (1) CA3162241A1 (pt)
IL (1) IL293165A (pt)
MX (1) MX2022006214A (pt)
WO (1) WO2021102345A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115887655A (zh) * 2021-09-30 2023-04-04 中国科学院脑科学与智能技术卓越创新中心 直接转分化治疗神经系统疾病
CN114377000A (zh) * 2021-12-24 2022-04-22 中山大学孙逸仙纪念医院 普瑞巴林在制备用于预防或治疗放射性脑损伤药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2019A (en) 1841-03-29 goedes
WO2002046403A2 (en) * 2000-12-05 2002-06-13 Bayer Aktiengesellschaft Regulation of human patched-like protein
EP2424877A4 (en) * 2009-04-28 2013-01-02 Harvard College SUPERCHARGED PROTEINS FOR CELL PENETRATION
US20120070419A1 (en) * 2010-03-25 2012-03-22 International Stem Cell Corporation Method of altering the differentiative state of a cell and compositions thereof
US20150299698A1 (en) 2012-11-01 2015-10-22 The Regents Of The University Of California Methods for engineering non-neuronal cells into neurons and using newly engineered neurons to treat neurodegenerative diseases
US20160031958A1 (en) * 2014-08-01 2016-02-04 Oregon Health & Science University Methods and compositions useful in manipulating the stability of re1 silencing transcription factor

Also Published As

Publication number Publication date
CN115023434A (zh) 2022-09-06
CA3162241A1 (en) 2021-05-14
WO2021102345A1 (en) 2021-05-27
IL293165A (en) 2022-07-01
AU2020386637A1 (en) 2022-06-16
EP4061833A4 (en) 2023-09-06
KR20220104008A (ko) 2022-07-25
JP2023503920A (ja) 2023-02-01
MX2022006214A (es) 2022-06-22
EP4061833A1 (en) 2022-09-28
US20230059411A1 (en) 2023-02-23

Similar Documents

Publication Publication Date Title
NZ587105A (en) Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
ITMI20021527A1 (it) Anticorpi anti componente c5 del complemento e loro uso
MX359516B (es) Composiciones y metodos para prevenir o tratar enfermedades, afecciones, o procesos caracterizados por la proliferacion abrellante de fibro blasto y deposicion de matriz extracelular.
BR112022009898A2 (pt) Composições e métodos para desrepressão de genes alvo do fator de transcrição silenciador de re1
EA200901067A1 (ru) Использование семафорина 6а в качестве промотора миелинизации и дифференцировки олигодендроцитов
Keifer et al. A microRNA-BDNF negative feedback signaling loop in brain: implications for Alzheimer’s disease
EA201171451A1 (ru) Генетические маркеры, ассоциированные с ответом на интерферон-альфа
US10683502B2 (en) Oligonucleotide decoys for the treatment of pain
TW200744642A (en) Novel peptides for use in the treatment of obesity
EA201892366A1 (ru) Антисмысловые олигомеры и способы их применения для лечения заболеваний, связанных с геном кислой альфа-глюкозидазы
MX2008009493A (es) Peptido novedoso y uso del mismo.
WO2011036443A9 (en) S1 protease c- terminal polypeptides and uses thereof for treating inflammation or coagulation disorders
NZ603028A (en) Tfpi inhibitors and methods of use
AR107579A1 (es) Composiciones y métodos para disminuir la expresión de tau
CO2017012454A2 (es) Secuencias de uricasa adecuadas para el tratamiento de hiperuricemia
RU2017145051A (ru) Внеклеточная днк в качестве терапевтической мишени при нейродегенерации
WO2012012600A3 (en) Peptide compounds for regulating the complement system
BR112015022469A2 (pt) peptídeo ou análogo seu, composição, método para melhorar um sinal ou sintoma, método para estimular o crescimento de células, método para produção de uma população de células, método para aumentar o número de células, método para redução em um indivíduo diabético da tolerância à glicose debilitada, método para a promoção de neuroproteção ou regeneração nervosa, método para a promoção da regeneração, método para a inibição de inflamação, composição farmacêutica e uso de um peptídeo ou análogo seu
JP2016519138A5 (pt)
MX2017006372A (es) Composiciones y metodos para prevenir o tratar enfermedades, condiciones o procesos caracterizados por proliferacion de fibroblasto aberrante y matrix extracelular.
EA201391387A1 (ru) Нейропротекторные пептиды
WO2013173827A3 (en) Methods and compositions for inhibiting diseases of the central nervous system
EA201691525A1 (ru) Применение кладрибина для лечения оптиконевромиелита
MX2017002476A (es) Composiciones y metodos para prevenir o tratar enfermedades, condiciones o procesos caracterizados por proliferacion de fibroblasto aberrante y matriz extracelular.
MX2020010807A (es) Peptidos promotores del crecimiento y usos de los mismos.

Legal Events

Date Code Title Description
B15I Others concerning applications: loss of priority

Free format text: PERDA DAS PRIORIDADES US 62/939,149 DE 22/11/2019 E US 63/086,248 DE 01/10/2020 REIVINDICADAS NO PCT/US2020/061632 POR NAO APRESENTACAO DE COPIA DO CORRESPONDENTE DOCUMENTO DE CESSAO DENTRO DO PRAZO LEGAL DE 60 DIAS APOS A PETICAO DE ENTRADA NA FASE NACIONAL DO BRASIL CONFORME AS DISPOSICOES PREVISTAS NO ART. 16 6O DA LEI 9.279 DE 14/05/1996 (LPI) E ART 19 2O DA PORTARIA INPI 39 DE 23/08/2021, UMA VEZ QUE DEPOSITANTE CONSTANTE DA PETICAO DE REQUERIMENTO DO PEDIDO PCT E DISTINTO DAQUELE QUE DEPOSITOU A PRIORIDADE REIVINDICADA.

B12F Other appeals [chapter 12.6 patent gazette]

Free format text: RECURSO: 870220104517 - 10/11/2022